PEPG250117C5000
- 0.00
- 0.000.00%
PepGen Newsroom
Wedbush Cuts Price Target on PepGen to $8 From $12, Maintains Outperform Rating
Leerink Partners Maintains PepGen(PEPG.US) With Buy Rating
BofA Securities Downgrades PepGen(PEPG.US) to Sell Rating, Cuts Target Price to $3
PepGen Shares Tumble Premarket as FDA Puts Study on Clinical Hold
PepGen Announces Clinical Hold In The U.S. On IND Application To Initiate CONNECT2-EDO51 Phase 2 Study Of PGN-EDO51 For Duchenne Muscular Dystrophy; Continues To Advance PGN-EDO51 In CONNECT1-EDO51, With The 10 Mg/kg Cohort Now Fully Enrolled
Express News | PepGen Announces Clinical Hold in the U.S. on Ind Application to Initiate Connect2-Edo51 Phase 2 Study of Pgn-Edo51 for Duchenne Muscular Dystrophy
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Express News | PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) to Newly Appointed Senior Vice President, Clinical Development
PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
Roku To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday
B of A Securities Maintains Neutral on PepGen, Lowers Price Target to $6
PepGen Inc. (PEPG) Receives a Buy From Stifel Nicolaus
PepGen Is Maintained at Outperform by Wedbush
Express News | PepGen Inc : Wedbush Cuts Target Price to $12 From $19
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $26
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), Ligand Pharma (LGND)
HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $26 Price Target
PepGen Analyst Ratings
PepGen GAAP EPS of -$0.66 Beats by $0.21